In summary, the combined treatment of DMF and anti-PD-L1 antibodies significantly inhibits tumor growth, indicating that DMF can enhance the efficacy of immune checkpoint blockade therapy in renal cancer. The gene discussed is CD274; the disease is renal carcinoma.